Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Stock Information for Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Agenus Reports Q1 2025 Financial Results and Key Business Updates
Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer
Agenus to Provide Corporate Update and First Quarter 2025 Financial Report
Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR
Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.